Topline results were announced from a phase 3 trial evaluating Xyngari™ (formerly DMT310), a novel topical treatment derived ...

Initial data readout on track for second half of 2025 HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., ...

CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Gearing Up for Phase 3 Trial of Tecarfarin Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is a biopharmaceutical company developing tecarfarin, a ...

Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin ... The failure of the ARTISTRY-7 clinical trial causes us to remain skeptical about the odds ...

- XYNGARI™ is the first once-weekly topical product candidate to demonstrate clinical benefit in a Phase 3 clinical trial for moderate-to-severe acne- - Over 30 million acne patients seek ...

Merck, known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase ...

The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.

Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in paroxysmal nocturnal ...

Topline data were announced from a phase 3 trial evaluating solriamfetol in adults with attention deficit hyperactivity disorder (ADHD).

With the newly completed OT-101 and IL-2 Phase 1 trial, Oncotelic is poised to begin further combination trials to determine the added efficacy of OT-101, IL-2, and CKIs in solid tumors such as lung ...